Sirolimus Gel Application Scope

Sirolimus Gel, a new and special drug, marketed under the brand name Hyftor, is a topical medication used to treat facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged 6 years and older.

sirolimus gel

Sirolimus Characteristics

Ingredients:
Active ingredient: Sirolimus.
Inactive ingredients: [Refer to the manufacturer’s official prescribing information for a complete list of excipients].
Properties:
Sirolimus is an mTOR inhibitor that reduces the size and appearance of facial angiofibromas by inhibiting cell growth and proliferation.
Packaging Specification:
Available in 10-gram tubes.
Storage:
Store at room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
Expiry Date:
Refer to the packaging for the expiration date.
Executive Standard:
Manufactured in compliance with Good Manufacturing Practices (GMP) and approved by relevant health authorities.
Approval Number:
[Specific approval number varies by country; refer to local regulatory information].
Date of Revision:
[Refer to the latest prescribing information for the most recent revision date].
Manufacturer:
Nobelpharma America, LLC.

Guidelines For The Use Of Sirolimus

Dosage and Administration:

Apply a thin layer to the affected areas of the face twice daily, in the morning and at bedtime.
For topical use only; not for oral, ophthalmic, or intravaginal use.
Do not use with occlusive dressings.

Adverse Reactions:
Common side effects may include application site reactions such as erythema, irritation, and pruritus.

Serious adverse reactions are rare but may include hypersensitivity reactions.

Monitor patients for signs and symptoms of these conditions.

Medication Limitations

Contraindications:

Hypersensitivity to sirolimus or any other component of the formulation.

Precautions:

Avoid exposure to sunlight and UV light; patients should use sunscreen and wear protective clothing.
Use with caution in patients with impaired wound healing.
Safety and effectiveness in pediatric patients under 6 years of age have not been established.

Sirolimus Interactions

Potential interaction with strong CYP3A4 inhibitors or inducers; consult healthcare provider before concurrent use.

Note: If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYueMed.

It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.